S
Cameron Durrant
WW VP, Global Strategic Marketing, Virology, J&J
YOU DIDN'T KNOW: While working as a physician, he opened a men's clothing company
Declaring a weakness is actually a strength." "You acquire more power by giving it up." Paradoxes like these are Cameron Durrant's stock-in-trade—visionary thinking about new leadership in pharma. "Tradition can be torn up," he says. "We can reinvent how we deliver value."
Cameron Durrant
Durrant's background is anything but traditional. "I grew up in pretty deprived circumstances," he recalls. "The school I went to—no one had gone to medical school before. 'It's just not possible,' I was told at 13." He took this as a challenge—and ultimately become an MD. "I see adversity as an opportunity to be resilient."
This preparation is perfect training to lead an industry facing unprecedented adversity. Currently running J&J's global strategic marketing for its virology portfolio (including HIV, hep C, and TB), Durrant is keen on creating "new healthcare partnerships, philanthropic models, ways of bringing information to customers."
He added business brains to his own portfolio by starting a medical devices company and heading strategic development at Pharmacia, among other jobs. This range has given Durrant a unique view on the industry's pitfalls and potentials. The only constant, he says, is change. The way forward is "servant leadership, greater transparency, [plus everything from] safe environments for employees to exquisite levels of service solutions for customers."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.